ATE399868T1 - Optimierte nukleotidsequenzen die für sgp130 kodieren - Google Patents

Optimierte nukleotidsequenzen die für sgp130 kodieren

Info

Publication number
ATE399868T1
ATE399868T1 AT04020455T AT04020455T ATE399868T1 AT E399868 T1 ATE399868 T1 AT E399868T1 AT 04020455 T AT04020455 T AT 04020455T AT 04020455 T AT04020455 T AT 04020455T AT E399868 T1 ATE399868 T1 AT E399868T1
Authority
AT
Austria
Prior art keywords
sgp130
nucleotide sequences
sequences encoding
optimized nucleotide
encoding sgp130
Prior art date
Application number
AT04020455T
Other languages
English (en)
Inventor
Dirk Seegert
Georg Waetzig
Nikolaus Rahaus
Jessica Daecke
Stefan Rose-John
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Application granted granted Critical
Publication of ATE399868T1 publication Critical patent/ATE399868T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
AT04020455T 2004-08-27 2004-08-27 Optimierte nukleotidsequenzen die für sgp130 kodieren ATE399868T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04020455A EP1630232B1 (de) 2004-08-27 2004-08-27 Optimierte Nukleotidsequenzen die für sgp130 kodieren

Publications (1)

Publication Number Publication Date
ATE399868T1 true ATE399868T1 (de) 2008-07-15

Family

ID=34926337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04020455T ATE399868T1 (de) 2004-08-27 2004-08-27 Optimierte nukleotidsequenzen die für sgp130 kodieren

Country Status (11)

Country Link
US (1) US8206948B2 (de)
EP (2) EP1630232B1 (de)
JP (1) JP4615016B2 (de)
AT (1) ATE399868T1 (de)
AU (1) AU2005276581A1 (de)
CA (1) CA2575800C (de)
DE (1) DE602004014758D1 (de)
DK (1) DK1630232T3 (de)
ES (1) ES2309427T3 (de)
PT (1) PT1630232E (de)
WO (1) WO2006021453A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
RS65665B1 (sr) 2014-12-01 2024-07-31 Ferring Bv Selektivne kompozicije inhibitora il-6-trans-signalizacije
EP3226888B1 (de) 2014-12-01 2021-04-21 Ferring B.V. Verabreichung eines selektiven il-6-transsignalisierenden inhibitors
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
CA3045871A1 (en) 2016-12-16 2018-06-21 Singapore Health Services Pte Ltd Il-11 antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
AU2020211695A1 (en) 2019-01-21 2021-09-02 National University Of Singapore Treatment of hepatotoxicity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
ES2298106T3 (es) * 2000-04-21 2008-05-16 Conaris Research Institute Ag Proteinas de fusion que comprenden dos moleculas gp130 solubles.
JP2004182638A (ja) * 2002-12-03 2004-07-02 Yakult Honsha Co Ltd 炎症性疾患又は悪性腫瘍の予防治療剤
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament

Also Published As

Publication number Publication date
US8206948B2 (en) 2012-06-26
EP1630232B1 (de) 2008-07-02
EP1791960A2 (de) 2007-06-06
PT1630232E (pt) 2008-10-02
DK1630232T3 (da) 2008-10-20
EP1630232A1 (de) 2006-03-01
JP4615016B2 (ja) 2011-01-19
WO2006021453A2 (en) 2006-03-02
ES2309427T3 (es) 2008-12-16
CA2575800A1 (en) 2006-03-02
US20080199906A1 (en) 2008-08-21
WO2006021453A3 (en) 2006-06-22
DE602004014758D1 (de) 2008-08-14
AU2005276581A1 (en) 2006-03-02
JP2008510474A (ja) 2008-04-10
CA2575800C (en) 2018-06-05

Similar Documents

Publication Publication Date Title
ATE530643T1 (de) Säureaktive fungale protease
DK2228440T3 (da) Varianter af beta-glucosidaser
ATE491788T1 (de) Proteasevarianten
ATE469971T1 (de) Mikroorganismen als träger von für antigene und proteintoxine codierende nukleotidsequenzen, verfahren zur herstellung und verwendungen davon
ATE500337T1 (de) Verfahren zur durchführung homologer rekombinationen in pflanzen
ATE491794T1 (de) Zusammensetzung und verfahren zur herstellung von steviolglykosiden
CO6341638A2 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
EA201170506A1 (ru) Генная терапия порфобилиногендезаминазой
ATE492633T1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
EP2302042A3 (de) Polypeptide mit Lipase-Aktivität und diese kodierende Polynukleotide
EA201001881A1 (ru) Пролинспецифичная протеаза из penicillium chrysogenum
WO2009097626A3 (en) Paired-end reads in sequencing by synthesis
NZ583783A (en) Avian interferon-lambda polypeptide and genetic sequences encoding the same
ATE454455T1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
EP2004852A4 (de) Amplifikation von dna-fragmenten
DE602004014758D1 (de) Optimierte Nukleotidsequenzen die für sgp130 kodieren
ATE533837T1 (de) Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen
EP2067857A4 (de) Verfahren zur dipeptidherstellung
WO2006076628A3 (en) Compositions comprising promoter sequences and methods of use
DE50212612D1 (de) Gene, die fuer kohlenstoffmetabolismus- und energieproduktions-proteine codieren
DE602006010990D1 (de) Verfahren zur dipeptidherstellung
ATE427996T1 (de) Verfahren zur herstellung von (s)-butan-2-ol
ATE420950T1 (de) Verfahren zur herstellung von lipasen
BRPI0618369A2 (pt) fator protéico de aumento de produtividade, novas linhas celulares e seus usos
ATE417938T1 (de) Neuartiges nukleotidgemisch für ein verbessertes nukleinsäureamplifikationsverfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1630232

Country of ref document: EP